Are GABAA Receptors Containing α5 Subunits Contributing to the Sedative Properties of Benzodiazepine Site Agonists?
- 28 March 2007
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 33 (2) , 332-339
- https://doi.org/10.1038/sj.npp.1301403
Abstract
Classical benzodiazepines (BZs) exert anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive, and amnesic effects through potentiation of neurotransmission at GABAA receptors containing α1, α2, α3 or α5 subunits. Genetic studies suggest that modulation at the α1 subunit contributes to much of the adverse effects of BZs, most notably sedation, ataxia, and amnesia. Hence, BZ site ligands functionally inactive at GABAA receptors containing the α1 subunit are considered to be promising leads for novel, anxioselective anxiolytics devoid of sedative properties. In pursuing this approach, we used two-electrode voltage clamp experiments in Xenopus oocytes expressing recombinant GABAA receptor subtypes to investigate functional selectivity of three newly synthesized BZ site ligands and also compared their in vivo behavioral profiles. The compounds were functionally selective for α2-, α3-, and α5-containing subtypes of GABAA receptors (SH-053-S-CH3 and SH-053-S-CH3-2′F) or essentially selective for α5 subtypes (SH-053-R-CH3). Possible influences on behavioral measures were tested in the elevated plus maze, spontaneous locomotor activity, and rotarod test, which are considered primarily predictive of the anxiolytic, sedative, and ataxic influence of BZs, respectively. The results confirmed the substantially diminished ataxic potential of BZ site agonists devoid of α1 subunit-mediated effects, with preserved anti-anxiety effects at 30 mg/kg of SH-053-S-CH3 and SH-053-S-CH3-2′F. However, all three ligands, dosed at 30 mg/kg, decreased spontaneous locomotor activity, suggesting that sedation may be partly dependent on activity mediated by α5-containing GABAA receptors. Hence, it could be of importance to avoid substantial agonist activity at α5 receptors by candidate anxioselective anxiolytics, if clinical sedation is to be avoided.Keywords
This publication has 36 references indexed in Scilit:
- Benzodiazepine site inverse agonists and locomotor activity in rats: Bimodal and biphasic influencePharmacology Biochemistry and Behavior, 2006
- Discovery of Imidazo[1,2-b][1,2,4]triazines as GABAA α2/3 Subtype Selective Agonists for the Treatment of AnxietyJournal of Medicinal Chemistry, 2006
- The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagocloneNeuropharmacology, 2006
- Contribution of GABAA Receptor Subtypes to the Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines: Studies with the Functionally Selective Ligand SL651498 [6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1 H-pyridol[3,4-b]indol-1-one]The Journal of Pharmacology and Experimental Therapeutics, 2005
- Analysis of GABAA Receptor Function and Dissection of the Pharmacology of Benzodiazepines and General Anesthetics Through Mouse GeneticsAnnual Review of Pharmacology and Toxicology, 2004
- Relationship between cerebral pharmacokinetics and anxiolytic activity of diazepam and its active metabolites after a single intra‐peritoneal administration of diazepam in miceHuman Psychopharmacology: Clinical and Experimental, 2002
- Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?European Neuropsychopharmacology, 1999
- The benzodiazepine binding site of GABAA receptorsPublished by Elsevier ,1997
- Endogenous [3H]flunitrazepam binding in human embryonic kidney cell line 293European Journal of Pharmacology: Molecular Pharmacology, 1995
- Methods in Behavioral Pharmacology: Techniques in the Behavioral and Neural Sciences, Volume 10: edited by Frans van Haaren, Elsevier, 1993. $108.50 (xxiii + 667 pages) ISBN G 306 44368 6Trends in Pharmacological Sciences, 1994